| __timestamp | Galapagos NV | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9079000 | 59644696 |
| Thursday, January 1, 2015 | 20309000 | 79541000 |
| Friday, January 1, 2016 | 16945000 | 98015000 |
| Sunday, January 1, 2017 | 20559000 | 103958000 |
| Monday, January 1, 2018 | 29641000 | 103654000 |
| Tuesday, January 1, 2019 | 88258000 | 128951000 |
| Wednesday, January 1, 2020 | 162170000 | 135799000 |
| Friday, January 1, 2021 | 167218000 | 149883000 |
| Saturday, January 1, 2022 | 239528000 | 220206000 |
| Sunday, January 1, 2023 | 94252000 | 265542000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Travere Therapeutics, Inc. and Galapagos NV have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Travere Therapeutics saw a steady increase in SG&A expenses, peaking at approximately 266% of their 2014 levels by 2023. In contrast, Galapagos NV experienced a more volatile trajectory, with expenses surging to nearly 264% of their 2014 levels by 2022, before dropping significantly in 2023. This fluctuation highlights the challenges and strategic decisions faced by biotech firms in balancing operational costs with research and development investments. As the industry evolves, these insights offer a glimpse into the financial strategies that can make or break a company's success.
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Bio-Techne Corporation vs Galapagos NV: SG&A Expense Trends
Walgreens Boots Alliance, Inc. or Galapagos NV: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Galapagos NV
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.